About US
Contact us
-
Novartis' Cosentyx can't top AbbVie's Humira in head-to-head psoriatic arthritis contestEli Lilly’s Taltz and Novartis’ Cosentyx have been battling it out lately in the next-gen psoriatic arthritis field. But Lilly’s drug has a big win under its belt that Novartis can’t tout. Friday, th2019/10/30
-
Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs sayAbbVie has a lot on its plate with a megamerger with Allergan in the works and the rollout of blockbuster hopeful Rinvoq. One thing it hasn't hadto worry about much is its blood cancer franchise––and2019/10/29
-
Novo preps for Rybelsus 'strike mode' as Ozempic hits blockbuster heightsNovo Nordisk's oral GLP-1Rybelsus rollout isn't yet showing up on its earnings reports, but, behind the scenes, the drugmaker is busy mapping out its key launch. The med, a follow-up to Novo'solder V2019/10/29
-
WuXi STA’s Jinshan Facility Passes EMA InspectionOctober 28, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility in Shanghai, China has successfully passed an inspect2019/10/28
-
Merck to lay off 500 workers around the U.S. in continued shift to innovative medsMerck, like many of its Big Pharma peers,is working to focus more on innovative drugs. But as part of that ongoing shift, the company is eliminating 500 positions nationwide. The company is cuttingjo2019/10/28
-
J&J reels after FDA finds 'sub-trace' levels of asbestos in its baby powderFor years, J&J has defended against lawsuits linking its talcum powder to cancer by saying the products are safe and don't contain asbestos.But Friday, J&J issued a recall, sayingthe FDA had2019/10/25
-
Pfizer, GSK, others face negligence suits over Zantac carcinogen testingDrugmakers are scrambling to pull Zantac off the shelves after a possible carcinogen was found in the heartburn med’s API. Now, a suite of federal lawsuits are claiming four companies declined to tes2019/10/25
-
Novartis' Zolgensma beats data woe, as Mayzent hits reimbursement hurdlesDespite initial payer resistance and lingering questions about possible regulatory crackdown on Novartis after the Zolgensma data manipulation scandal, the costly spinal muscular atrophy gene therapy2019/10/24
-
BMS nets another Opdivo lung cancer win—but it still has to beat Merck's high barIt’s been a rocky road for Bristol-Myers Squibb’s immuno-oncology duo in previously untreated non-small cell lung cancer (NSCLC), but a new addition to the regimen might hold the ticket. Tuesday, the2019/10/24
-
Vertex lands $6B-plus triple combo nod for CF drug Trikafta—5 months earlyThe triple combo era in cystic fibrosis is here thanks to a Monday Vertex Pharmaceuticals approval—and it’s here earlier than industry watchers expected. A lot earlier. Five months ahead of schedule—2019/10/23